Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Xenon Pharmaceuticals Q3 EPS $(1.15), Inline. Cash And Equivalents $555.3M

Author: Benzinga Newsdesk | November 03, 2025 04:02pm
Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(1.15) per share which met the analyst consensus estimate. This is a 41.98 percent decrease over losses of $(0.81) per share from the same period last year.

Posted In: XENE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist